1. Introduction {#sec1}
===============

Inflammatory bowel diseases (IBD) encompass a group of chronic nonspecific inflammatory diseases of the bowel with unknown aetiology. The main forms of IBD are ulcerative colitis (UC) and Crohn\'s disease (CD). UC and CD are similar with regard to their clinical manifestations, diagnosis, and treatment. Clinically, both UC and CD involve the primary symptoms of abdominal pain and diarrhoea. These conditions are refractory and recurrent, causing high levels of patient suffering.

The aetiology and pathogenesis of IBD are not fully understood and, moreover, there is currently no specific treatment. The primary therapeutic approaches in clinical practice are derived from western medicine including traditional treatment with sulphasalazine (SASP; also known as 5-aminosalicyclic acid (5-ASA)) or the administration of steroids, immunosuppressive agents, or new biological agents. However, long-term treatment with steroids and immunosuppressants can cause serious adverse reactions, whereas new types of biological agents not only are expensive and economically burdensome to patients but also have unsatisfactory long-term efficacy.

Since the 1990s, there have been an increasing number of clinical studies of acupuncture and moxibustion treatment for IBD, and the existing investigations have demonstrated that acupuncture and moxibustion can effectively control bowel inflammation by providing multitargeted regulation of the body\'s physiological balance \[[@B1], [@B2]\]. However, quality of these clinical studies is uneven, and types are varied. So far, systematic reviews or meta-analyses about acupuncture and moxibustion treatment for IBD are few. Therefore, it is necessary to conduct systematic evaluations and meta-analysis of randomized controlled trials (RCTs) of acupuncture and moxibustion in treating IBD. Also the studies could provide a reference for future clinical treatment and research.

2. Materials and Methods {#sec2}
========================

2.1. Search and Retrieval Strategy {#sec2.1}
----------------------------------

Foreign-language and Chinese databases were searched. The Medline, Embase, and Cochrane Library databases were searched for English-language reports regarding RCTs. The Medline database was searched from 1966 to December 31, 2012, and Embase from 1974 to December 31, 2012. The Chinese literature databases that were searched include the China National Knowledge Infrastructure Database (CNKI), the Chongqing VIP Chinese Science and Technology Periodical Database (VIP), and the Chinese Biomedical Literature Database (CBM). The CNKI and CBM were searched to retrieve relevant studies from January 1, 1949, to December 31, 2012, whereas the VIP was searched to retrieve relevant studies from January 1, 1989, to December 31, 2012. The keywords used to for the Chinese-language literature include "inflammatory bowel diseases," "ulcerative colitis", "Crohn\'s disease", "acupuncture", "moxibustion", "acupoint", and "acupuncture treatment"; the keywords used for English-language literature included "acupuncture", "moxibustion", "inflammatory bowel diseases," "ulcerative colitis", and "Crohn\'s disease" Based on the specific circumstances of the different databases, comprehensive searches for combinations of keywords and for wildcards were conducted to ensure the completeness of the search results.

2.2. Inclusion Criteria {#sec2.2}
-----------------------

\(1\) Research subjects: included studies were required to have enrolled patients with an unequivocal diagnosis of IBD (including UC and CD); no restrictions on race, age, or sex were imposed. (2) Study design: included studies were required to be RCTs in Chinese or English that evaluated the efficacy of acupuncture and/or moxibustion treatment for IBD. (3) Experimental group interventions: included studies were required to feature an experimental group that mainly received acupuncture and/or moxibustion treatment (including filiform needles, electroacupuncture, moxibustion, or cupping, among other techniques), either alone or in conjunction with other therapies (such as drug therapy), without differentiating among different acupuncture and moxibustion techniques, the selection of acupoints, or needle material. For studies in which the treatment group received acupuncture and/or moxibustion treatment combined with medication, the same drug had to be administered to both the treatment group and the control group. (4) Control group interventions: included studies were required to feature a control group that received medication, placebo, or sham acupuncture controlled treatment(s). (5) Outcome measurements: the outcome measurements of included studies had to include overall clinical efficacy, general conditions, changes in symptoms, serum inflammatory markers, and/or colonoscopic findings. (6) Availability: the full text or sufficiently informative abstracts of included studies had to be accessible.

2.3. Exclusion Criteria {#sec2.3}
-----------------------

The following types of studies were excluded from this analysis: (1) RCTs that lacked clear diagnostic criteria or basic information of the subjects or interventions; (2) serial observations, case reports, expert experiences, or descriptive analyses without control groups; (3) studies that compared different acupuncture and moxibustion techniques or selection of different acupoints to control groups; (4) studies that compared acupoint injections to drug therapy; (6) studies that were duplicate for retrieving or publishing.

2.4. Quality Assessments of the Included RCTs {#sec2.4}
---------------------------------------------

The methodological quality of the included trials was evaluated using a modified Jadad quality scale ([Table 1](#tab1){ref-type="table"}). The total possible score for study quality was 7 points. Studies with scores of 1--3 points were regarded as low-quality investigations, and studies with scores of 4--7 points were regarded as high-quality investigations.

2.5. Data Retrieval {#sec2.5}
-------------------

In accordance with the predetermined inclusion criteria, two researchers independently performed a rigorous screening to identify qualified trials, and they extracted data from these trials using a predesigned data extraction form independently. The extracted data included methodological features of the studies, demographic characteristics, treatment and control measurements, and primary outcome indicators. A third evaluator verified the consistency of the data, and any inconsistencies were addressed through discussion.

2.6. Data Analysis {#sec2.6}
------------------

The RevMan software package from the Cochrane Collaboration (Oxford, UK), version 5.1, was used for meta-analysis of the data. In the analysis of clinical efficacy, count data were assessed in terms of risk ratios (RRs), and continuous variables were assessed in terms of mean difference (MD). Both count data and continuous variables are expressed as efficacy values with 95% confidence intervals (CIs). If the meta-analysis results exhibited heterogeneity (defined as results of tests of heterogeneity that indicated that *P* \< 0.1 and *I* ^2^ ≥ 50%), then a random effects model will be used to assess combined efficacy values; otherwise, fixed effects models will be used for these assessments. Funnel plot analysis was used to evaluate the presence of publication bias.

3. Results {#sec3}
==========

3.1. The Characteristics and Methodological Quality of the Included Trials {#sec3.1}
--------------------------------------------------------------------------

Using the search and retrieval strategy, a total of 746 studies were initially retrieved from the six aforementioned medical databases, including 152 English studies and 594 Chinese studies. The bibliographic information for these studies was imported into Microsoft Excel, and 348 duplicated titles were deleted. The titles and abstracts of the remaining studies were read to exclude irrelevant studies; after this process, 195 studies remained. These 195 studies were downloaded and full texts were read; using the pre-determined exclusion criteria, 152 irrelevant studies were excluded. Finally, 43 studies were selected for inclusion \[[@B3]--[@B45]\], including 37 studies in Chinese and six studies in English. All of the included studies were published as journal articles. The flowchart for the literature search process is presented in [Figure 1](#fig1){ref-type="fig"}.

Among the 43 included studies, there was one CD study \[[@B43]\] and 42 UC studies. These studies included a total of 4,021 patients with IBD; 2,146 of these patients were male (55.9%), 1,691 were female (44.1%), and the gender of the remaining 184 patients (4.6%) was unknown because two studies did not report this information \[[@B5], [@B31]\]. The average sample size of each included RCT was 93.5 and ranged from 29 to 640.

Acupuncture and moxibustion therapy was the main intervention in the treatment groups of the examined RCTs. These treatments primarily involved acupuncture and/or moxibustion, although certain studies examined acupoint catgut embedding therapy, acupoint application, and auricular acupressure. In particular, among the 43 included studies, acupuncture and moxibustion therapy was used as the intervention method for the treatment group in 17 studies \[[@B5], [@B8], [@B9], [@B13]--[@B19], [@B21], [@B23]--[@B25], [@B28], [@B36], [@B45]\]; moxibustion treatment was used as the main intervention in 12 studies \[[@B5], [@B8], [@B9], [@B13]--[@B19], [@B28], [@B36]\]; acupuncture alone was used in one study \[[@B45]\]; acupoint catgut embedding therapy was used in two studies \[[@B24], [@B25]\]; balance cupping therapy was used in one study \[[@B21]\]; and acupoint application was used in one study \[[@B23]\]. Comprehensive treatment, using two forms of therapy as an intervention method, was used in 19 studies \[[@B3], [@B6], [@B7], [@B12], [@B20], [@B22], [@B26], [@B27], [@B29], [@B31], [@B33], [@B35], [@B37], [@B39]--[@B44]\]; in particular, combinations of two types of acupuncture and moxibustion treatments were used in 10 studies \[[@B3], [@B12], [@B22], [@B29], [@B35], [@B37], [@B41]--[@B44]\]; a combination of acupuncture and moxibustion with SASP treatments was used in three studies \[[@B6], [@B20], [@B39]\]; a combination of acupuncture and moxibustion with Chinese herbal treatments was used in one study \[[@B40]\]; and a combination of acupuncture and moxibustion with a retention enema, using traditional Chinese medicine, was used in five studies \[[@B7], [@B26], [@B27], [@B31], [@B33]\]. A combination of three treatments was used as an intervention method in a total of six studies \[[@B4], [@B10], [@B30], [@B32], [@B34], [@B38]\]; in particular, a combination of three types of acupuncture and moxibustion techniques was used in one study \[[@B38]\]; a combination of two types of acupuncture and moxibustion techniques and a retention enema using traditional Chinese medicine and/or western drugs was used in two studies \[[@B32], [@B34]\]; a combination of two types of acupuncture and moxibustion techniques with Chinese herbal medicine was used in one study \[[@B4]\]; and a combination therapy of two types of acupuncture and moxibustion techniques with oral western medicine was used in two studies \[[@B10], [@B30]\]. In addition, a combination of four interventions, including auricular acupressure, oral Chinese medicine, oral western medicine, and an enema with traditional Chinese medicine, was used in one study \[[@B11]\]. The interventions for the control groups consisted of drug therapy; in particular, most of these studies involved a control group that was administered SASP (27 studies). In addition, sham acupuncture was used as a control in two studies \[[@B41], [@B43]\].

The main outcome indicators reported in the included studies were overall efficacy, colonic activity indices, clinical symptom scores, fibre colonoscopy results, laboratory test findings (including evaluations of T lymphocyte subpopulations and immunoglobulin), and adverse reactions to treatments. The general data and methodological quality of the included studies are presented in [Table 2](#tab2){ref-type="table"}, and the interventions and outcome measurements are presented in [Table 3](#tab3){ref-type="table"}.

The assessments for bias risk revealed that among the 43 RCTs included in this systematic evaluation, nine RCTs reported their random allocation methods \[[@B10]--[@B12], [@B18], [@B25], [@B29], [@B40], [@B41], [@B43]\], three studies utilized appropriate allocation concealment \[[@B10], [@B41], [@B43]\], and the random allocation methods and allocation concealment of the remaining trials were either inappropriate or unclear. One study reported using a single-blind approach \[[@B41]\], one study addressed its implementation of a single-blind design and the reasons underlying the failure of final implementation \[[@B43]\], and unclear descriptions of blinding were provided in two trials \[[@B30], [@B37]\]. Two studies reported the numbers and the reasons of withdrawals from the trials \[[@B41], [@B43]\]. One study utilised preliminary screening to estimate its sample size before its main experiments \[[@B41]\]. In general, the methodological and report qualities of the included studies were low. Four trials reported follow-up data \[[@B10], [@B22], [@B41], [@B43]\]. In particular, Zhou and Jin \[[@B10]\] reported that at the 1-year followup, the recurrence rate was significantly lower in the treatment group than in the control group (*P* \< 0.05). Li et al. \[[@B22]\] observed that by the 2-year followup, 11 patients in the treatment group and 12 patients in the control group had experienced recurrences. In a 2004 CD study, Joos et al. \[[@B43]\] found that the efficacy was fundamentally maintained for 12 weeks of followup after treatment (*P* = 0.059), and the same research group reported in their 2006 UC study \[[@B41]\] that after 16-week follow-up, the primary outcome measurements remained more significantly improved than receiving treatment before (*P* \< 0.001). The remaining included RCTs did not mention follow-up.

3.2. Results of Studies with High Jadad Scores {#sec3.2}
----------------------------------------------

Three of the 43 included trials were of high quality \[[@B10], [@B41], [@B43]\]. Zhou and Jin \[[@B10]\] utilised an RCT to observe the efficacy in UC patients of electroacupuncture combined with ginger-partitioned moxibustion and oral SASP treatment. 220 patients in this trial were randomly divided into the treatment group (*n* = 110) and the SASP control group (*n* = 110); the overall clinical efficacy of the treatment group was 84.5%, which was significantly better than the control treatment (68.2%, *P* \< 0.05). In a 2004 study of CD \[[@B43]\] and a 2006 study of UC \[[@B41]\], Joos et al. examined the treatment efficacy of acupuncture combined with moxibustion, with sham acupuncture (i.e., shallow punctures at non-acupoints) as a control, in investigations that featured the rigorous design and implementation of a prospective, randomized, controlled, single-blind trial (although the researchers reported that the implementation of the single-blind design was unsuccessful in their 2004 CD study). In the 2004 study, Joos et al. randomly divided 51 CD patients into traditional Chinese medicine (TCM) group (acupuncture combined with moxibustion, *n* = 27) and control group (sham acupuncture, *n* = 24). After 4 weeks of treatment, the CD Activity Index (CDAI) of the patients in the TCM group had decreased significantly and was superior to the control group (*P* = 0.003). In their 2006 study, Joos et al. randomly divided 29 UC patients into TCM group (acupuncture combined with moxibustion, *n* = 15) and control group (sham acupuncture, *n* = 14); after 5 weeks of treatment, the Colitis Activity Index (CAI) of the patients in the traditional Chinese medicine group was significantly lower than the CAI of the control group (*P* = 0.048).

3.3. Meta-Analysis Results {#sec3.3}
--------------------------

The 43 included RCTs featured complex interventions and different reported outcomes, with no unified efficacy standard. To develop a general understanding of the therapeutic effect of acupuncture and moxibustion therapy for IBD, intervention measurements and therapies for control group were further refined. We limited the treatment group methods to acupuncture or moxibustion alone, or a combination of acupuncture and moxibustion; this limitation produced 10 studies that compared one of the these treatments with oral SASP for the treatment of UC \[[@B5], [@B14]--[@B16], [@B18], [@B19], [@B37], [@B42], [@B44], [@B45]\]. We then conducted a comprehensive efficacy evaluation of the interventions in the 10 RCTs, which featured simple interventions that could be readily compared with oral SASP. In addition, the efficacy criteria for these RCTs were similar, featuring the three outcomes of recently cured, effective, and ineffective; judgements of these outcomes were based on various indicators, such as clinical manifestations, routine stool test results, and colonoscopy findings. The definition of ineffective treatment was consistent among these 10 studies; therefore, a meta-analysis of the overall clinical efficacies determined in these studies could be performed.

### 3.3.1. Analysis of Overall Clinical Efficacy {#sec3.3.1}

The results of heterogeneity tests indicated that *I* ^2^ \< 50% and *P* \> 0.1 for the 10 examined studies and that the overall heterogeneity of subgroups was small (*P* = 0.28, *I* ^2^ = 17%); therefore, a fixed effects model was used. The overall efficacy of acupuncture alone, moxibustion alone, or acupuncture combined with moxibustion was greater than the efficacy of western medicine (oral SASP) for the treatment of IBD (*P* \< 0.00001, RR = 5.42, 95% CI \[3.38, 8.68\]) ([Figure 2](#fig2){ref-type="fig"}).

3.4. Funnel Plot {#sec3.4}
----------------

RevMan, version 5.1, was used to conduct a funnel plot analysis of the aforementioned 10 studies, and the resulting graph was symmetrical, suggesting that these studies demonstrated no obvious publication bias ([Figure 3](#fig3){ref-type="fig"}).

4. Discussion {#sec4}
=============

4.1. Methodological Quality of the Included Trials {#sec4.1}
--------------------------------------------------

Based on the RCTs examined in this study, the methodological quality of the clinical trials regarding the examined topic was generally low, and few studies provided robust evidence. Randomization and allocation concealment are among the ways in which bias can arise, and the vast majority of the examined trials only mentioned "randomization", without describing the specific methods used or whether allocation concealment was implemented. Thus, nonstandard "randomization" was widespread. The selective reporting of research results or the loss of trial data can also lead to reporting bias. Among the 43 included trials, only two studies reported the numbers of withdrawals from the study and the reasons; because none of the other trials reported exit data or cases lost to followup, the efficacy conclusions of these trials might be exaggerated. Most of the studies did not utilize blinding, producing a high probability of bias. The overall quality of the studies was low, affecting the strength of the evidence that was examined in this systematic evaluation.

4.2. Determinations of Sample Size {#sec4.2}
----------------------------------

Adequate attention must be devoted to the important factor of sample size in RCTs that address the examined topic. At present, only two relevant RCTs have featured sample sizes of more than 200 individuals. Insufficient sample sizes can reduce the power of a test, resulting in limited reliability of the results and conclusions, that do not truly reflect the overall effects observed in a study. Low statistical power will reduce the magnitude of evidence that RCTs can provide.

4.3. Selection of Interventions {#sec4.3}
-------------------------------

In this study, the specific interventions described in the included studies, which included acupuncture, herb-partitioned moxibustion, ginger-partitioned moxibustion, moxibustion, electroacupuncture, abdominal acupuncture, acupuncture catgut embedding, acupoint application, cupping, and auricular pressure, were treated as one type of therapy, without considering the differences in acupoint selection or therapeutic techniques. Therefore, the results of this study might indicate overall efficacy trends, but they cannot be utilised to draw definitive conclusions, thus limiting the extent to which the conclusions of this investigation can be applied.

4.4. The Selection and Measurement of Outcome Indicators {#sec4.4}
--------------------------------------------------------

The majority of the included studies selected clinical efficacy as the outcome measurement. Thus, there may exist subjectivity in the evaluations of the results. With little use of objective indicators, such as clinical symptom scores, endoscopic scores, or pathologic scores, the tendency towards subjective judgements weakened the credibility of conclusions regarding the effectiveness of acupuncture and moxibustion. With regard to long-term efficacy, most of the included studies did not conduct long-term followup, or if someone did, either the data for withdraw or the follow-up methods were not described. As a result, the long-term efficacy of acupuncture and moxibustion treatment for IBD cannot be determined.

4.5. Suggestions for Future Research {#sec4.5}
------------------------------------

The objectivity and accuracy of systematic evaluations rely on high-quality RCTs. The findings of this systematic evaluation are somewhat limited due to the generally low quality of the existing studies. Thus, it is recommended that future research should be based on the Consolidated Standards of Reporting Trials (CONSORT) statement \[[@B46]\]. In particular, future studies should provide detailed reports regarding the generation of random allocation sequences and allocation concealment; moreover, to the greatest possible extent, these studies should be blinded and placebo controlled. In addition, a subject flowchart should be utilised to provide detailed accounts of patient withdrawals and loss during trials. Followup should be strengthened, and all of the trial data should be completely reported. In addition, intent-to-treat analysis should be conducted to evaluate therapeutic effects. These measurements will produce clinical RCTs that provide high levels of reliable evidence.

5. Conclusion {#sec5}
=============

The results of this study suggest that acupuncture and moxibustion treatment demonstrated better overall efficacy than oral SASP in treating IBD. However, given the limitations of this systematic evaluation and the included studies, definitive conclusions cannot be drawn with regard to the specific efficacy of acupuncture and moxibustion treatment for IBD. Currently published RCTs have not provided sufficient evidence for the effectiveness of acupuncture and moxibustion for IBD; thus, multicentre, double-blind RCTs with large sample sizes are still required to provide higher levels of evidence.
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###### 

Modified Jadad quality scale.

  Aspects                                                                                                                                                                                                Details                                                                                                                                                                                                                                                                           Score
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  Randomization                                                                                                                                                                                          Appropriate if random sequence is generated by computer or similar methods                                                                                                                                                                                                        2
  Unclear if a trial does not describe its method of randomization                                                                                                                                       1                                                                                                                                                                                                                                                                                 
  Inappropriate if a study uses an alternate assignment method, such as the allocation of odd and even numbers                                                                                           0                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Randomization concealment                                                                                                                                                                              Appropriate if either the distribution scheme is controlled by a center or pharmacy, containers with consistent serial numbers being used, on-site computer control, sealed opaque envelopes, or any other allocation method that clinicians and subjects are unable to predict   2
  Unclear if only a random number table or other random allocation scheme is employed                                                                                                                    1                                                                                                                                                                                                                                                                                 
  Inappropriate if either of alternate allocation, case numbers, days of the week, an open-label random number table, serial coded envelopes, or any other method with predictable assignments is used   0                                                                                                                                                                                                                                                                                 
  Absent if randomization is not used                                                                                                                                                                    0                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Blinding method                                                                                                                                                                                        Appropriate if a completely identical placebo form or a similar method is used                                                                                                                                                                                                    2
  Unclear if the trial was described as blinded, but no methodological information regarding the blinding was provided                                                                                   1                                                                                                                                                                                                                                                                                 
  Inappropriate if the double-blind method is not adopted or if the blinding method is improper, such as a comparison between tablets and injections                                                     0                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Withdrawal and exit                                                                                                                                                                                    The number and reasons of patients who withdraw or exit are described                                                                                                                                                                                                             1
  The number and reasons of patients who withdraw or exit are not described                                                                                                                              0                                                                                                                                                                                                                                                                                 

###### 

Characteristics and methodological quality of included studies.

  Study                               Sample size (*n* ~1~/*n* ~2~)   Sex (male/female)   Age (mean or range)        Type of IBD   Followup   Methodology quality score
  ----------------------------------- ------------------------------- ------------------- -------------------------- ------------- ---------- ---------------------------
  Ma and Zhang, 1997 \[[@B3]\]        90 (60/30)                      56/34               *T*: 23--68; *C*: 28--65   UC            No         1
  Gao, 1997 \[[@B4]\]                 66 (46/20)                      27/39               *T*: 43.6; *C*: 39.5       UC            No         1
  Wu et al., 1999 \[[@B5]\]           151 (65/56/30)                  ND                  *T*: 42.7; *C*: 38.4       UC            No         1
  Li et al., 2008 \[[@B6]\]           67 (34/33)                      42/25               35.5                       UC            No         1
  Mo et al., 2010 \[[@B7]\]           62 (31/31)                      35/27               35.5                       UC            No         1
  X. Guo and F. Guo, 2010 \[[@B8]\]   55 (28/27)                      38/17               38.77                      UC            No         1
  Yang et al., 2011 \[[@B9]\]         100 (50/50)                     61/39               *T*: 54.6; *C*: 55.3       UC            No         1
  Zhou and Jin, 2008 \[[@B10]\]       220 (110/110)                   131/89              *T*: 48.60; *C*: 50.24     UC            Yes        4
  Han et al., 2012 \[[@B11]\]         81 (41/40)                      47/34               *T*: 36.5; *C*: 34.7       UC            No         1
  Jiang, 2012 \[[@B12]\]              80 (40/40)                      39/41               *T*: 38.65; *C*: 39.35     UC            No         3
  Zhou, 2003 \[[@B13]\]               66 (34/32)                      31/35               40.8                       UC            No         1
  Din et al., 2009 \[[@B14]\]         61 (30/31)                      32/29               *T*: 44.9; *C*: 40.2       UC            No         1
  Wu et al., 2000 \[[@B15]\]          46 (30/16)                      25/21               *T*: 38.75; *C*: 37        UC            No         1
  Wen, 2003 \[[@B16]\]                69 (39/30)                      35/34               *T*: 41.2; *C*: 37.4       UC            No         1
  Wang et al., 2006 \[[@B17]\]        60 (30/30)                      28/32               38.5                       UC            No         1
  Xu et al., 2010 \[[@B18]\]          60 (28/32)                      35/25               *T*: 35.0; *C*: 37.0       UC            No         2
  Zhang, 2012 \[[@B19]\]              60 (30/30)                      32/28               *T*: 28--52; *C*: 27--55   UC            No         1
  Chi and Yu, 2011 \[[@B20]\]         84 (44/40)                      36/48               *T*: 45; *C*: 43           UC            No         1
  Luo, 2009 \[[@B21]\]                76 (40/36)                      42/34               *T*: 53; *C*: 51.3         UC            No         1
  Li et al., 2006 \[[@B22]\]          68 (40/28)                      40/28               *T*: 36.4; *C*: 38.2       UC            Yes        1
  Tian et al., 2012 \[[@B23]\]        106 (53/53)                     46/60               *T*: 29--61; *C*: 32--63   UC            No         1
  Chen, 2004 \[[@B24]\]               130 (100/30)                    80/50               *T*: 42.5; *C*: 40.2       UC            No         1
  Li et al., 2006 \[[@B25]\]          116 (56/60)                     52/64               *T*: 37.1; *C*: 37.3       UC            No         2
  Duan et al., 2012 \[[@B26]\]        640 (320/320)                   406/234             *T*: 45.5; *C*: 46.5       UC            No         1
  Sun and Wang, 1998 \[[@B27]\]       88 (45/43)                      43/45               *T*: 34.6; *C*: 33.8       UC            No         1
  Wang, 2008 \[[@B28]\]               108 (54/54)                     78/30               *T*: 35; *C*: 33.5         UC            No         1
  Ma and Xu, 2005 \[[@B29]\]          92 (47/45)                      51/41               *T*: 52.5; *C*: 52.5       UC            No         2
  Cui, 2010 \[[@B30]\]                48 (24/24)                      27/21               *T*: 43; *C*: 44           UC            No         2
  Guo et al., 2007 \[[@B31]\]         33 (22/11)                      ND                  ND                         UC            No         1
  Wang et al., 2009 \[[@B32]\]        78 (39/39)                      44/34               *T*: 57.5; *C*: 55.0       UC            No         1
  Long and Yang, 2010 \[[@B33]\]      46 (23/23)                      20/26               *T*: 33.5; *C*: 33.4       UC            No         1
  Chen, 2010 \[[@B34]\]               168 (84/84)                     91/77               38.4                       UC            No         1
  Sun and Wang, 2001 \[[@B35]\]       55 (35/20)                      32/23               *T*: 22--65; *C*: 25--70   UC            No         1
  Wang et al., 2006 \[[@B36]\]        45 (27/18)                      23/22               40.5                       UC            No         1
  Shi et al., 2006 \[[@B37]\]         60 (30/30)                      34/26               *T*: 42.31; *C*: 43.64     UC            No         2
  Qun et al., 2012 \[[@B38]\]         63 (33/30)                      32/31               *T*: 46; *C*: 41           UC            No         1
  Xu, 2006 \[[@B39]\]                 110 (56/54)                     59/51               *T*: 35.5; *C*: 33         UC            No         1
  Zhang et al., 2011 \[[@B40]\]       60 (30/30)                      38/22               *T*: 31.2; *C*: 30.6       UC            No         2
  Joos et al., 2006 \[[@B41]\]        29 (15/14)                      10/19               37.89 ± 12.0               UC            Yes        7
  Yang and Yan, 1999 \[[@B42]\]       62 (32/30)                      30/32               *T*: 45.5; *C*: 50.1       UC            No         1
  Joos et al., 2004 \[[@B43]\]        51 (27/24)                      15/36               ND                         CD            Yes        5
  Ma, 1999 \[[@B44]\]                 90 (60/30)                      56/34               *T*: 23--68; *C*: 28--65   UC            No         1
  Ma, 2005 \[[@B45]\]                 121 (76/45)                     67/54               *T*: 42; *C*: 41.5         UC            No         1

*n* ~1~: sample size of test group; *n* ~2~: sample size of control group; *T*: test group; *C*: control group; ND: not described; IBD: inflammatory bowel disease; UC: ulcerative colitis; CD: Crohn\'s disease.

###### 

Interventions and outcomes of included studies.

  Study                               Intervention                                                                                                              Control                                                                                           Outcome measurement
  ----------------------------------- ------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------
  Ma and Zhang, 1997 \[[@B3]\]        Acupuncture + sparrow-pecking moxibustion                                                                                 SASP + metronidazole                                                                              Efficacy
  Gao, 1997 \[[@B4]\]                 Acupoint application + moxibustion + decoction of traditional Chinese medicine                                            Traditional Chinese medicine                                                                      Efficacy
  Wu et al., 1999 \[[@B5]\]           Drug-separated moxibustion                                                                                                SASP                                                                                              Efficacy, T lymphocyte subpopulations, HLA-DR antigen
  Li et al., 2008 \[[@B6]\]           Moxa-box moxibustion + SASP                                                                                               SASP                                                                                              Efficacy, haemorheology, immunoglobulin, T lymphocyte subpopulations
  Mo et al., 2010 \[[@B7]\]           Moxa-box moxibustion + traditional Chinese medicine enema                                                                 Traditional Chinese medicine enema                                                                Efficacy
  X. Guo and F. Guo, 2010 \[[@B8]\]   Warm moxibustion of acupoints                                                                                             SASP + PAT                                                                                        Efficacy, T lymphocyte subpopulations
  Yang et al., 2011 \[[@B9]\]         Ginger moxibustion                                                                                                        Diphenoxylate                                                                                     Efficacy
  Zhou and Jin, 2008 \[[@B10]\]       Electroacupuncture + ginger moxibustion + SASP                                                                            SASP                                                                                              Medical condition, efficacy, intestinal mucosa pathology, adverse reactions
  Han et al., 2012 \[[@B11]\]         Auricular acupressure + salicylic acid preparations + traditional Chinese medicine + traditional Chinese medicine enema   Salicylic acid preparations + traditional Chinese medicine + traditional Chinese medicine enema   Enema retention time, efficacy
  Jiang, 2012 \[[@B12]\]              Abdominal acupuncture + acupoint catgut embedding                                                                         Bupi Yichang pills                                                                                Symptom scores, efficacy, fibre colonoscopy
  Zhou, 2003 \[[@B13]\]               Ginger moxibustion                                                                                                        SASP + prednisone tablets                                                                         Efficacy
  Din et al., 2009 \[[@B14]\]         Ginger moxibustion                                                                                                        SASP                                                                                              Efficacy
  Wu et al., 2000 \[[@B15]\]          Moxibustion with herbal medicine underneath                                                                               SASP                                                                                              Efficacy, colonic mucosal histopathology, mucin
  Wen, 2003 \[[@B16]\]                Drug-separated moxibustion                                                                                                SASP                                                                                              Efficacy, immunoglobulin
  Wang et al., 2006 \[[@B17]\]        Drug-separated moxibustion                                                                                                SASP + metronidazole tablets                                                                      Efficacy, immunoglobulin, T lymphocyte subpopulations, NK content
  Xu et al., 2010 \[[@B18]\]          Herb-partitioned moxibustion                                                                                              SASP                                                                                              Efficacy, adverse reactions
  Zhang, 2012 \[[@B19]\]              Drug-separated moxibustion                                                                                                SASP                                                                                              Efficacy
  Chi and Yu, 2011 \[[@B20]\]         Umbilical compression with traditional Chinese medicine + SASP                                                            SASP                                                                                              Efficacy
  Luo, 2009 \[[@B21]\]                Balance cupping                                                                                                           Enteritidis tablet                                                                                Efficacy, symptom scores, immunoglobulin
  Li et al., 2006 \[[@B22]\]          Application of musky warm umbilical cream + use of a specific electromagnetic spectrum therapeutic apparatus              SASP                                                                                              Efficacy
  Tian et al., 2012 \[[@B23]\]        Acupoint application                                                                                                      SASP                                                                                              Efficacy, symptom scores
  Chen, 2004 \[[@B24]\]               Acupoint catgut embedding                                                                                                 SASP                                                                                              Efficacy
  Li et al., 2006 \[[@B25]\]          Acupoint catgut embedding                                                                                                 SASP                                                                                              Efficacy, stool characteristics, abdominal pain
  Duan et al., 2012 \[[@B26]\]        Acupoint catgut embedding + traditional Chinese medicine enema                                                            Traditional Chinese medicine enema                                                                Efficacy, routine stool tests
  Sun and Wang, 1998 \[[@B27]\]       Warm acupuncture + traditional Chinese medicine enema                                                                     Traditional Chinese medicine enema                                                                Efficacy
  Wang, 2008 \[[@B28]\]               Warm acupuncture                                                                                                          SASP + western medicine enema                                                                     Efficacy
  Ma and Xu, 2005 \[[@B29]\]          Acupuncture + TDP                                                                                                         SASP                                                                                              Efficacy
  Cui, 2010 \[[@B30]\]                Acupuncture + moxibustion + SASP                                                                                          SASP                                                                                              Efficacy, serum levels of TNF-*α*, IL-1, and IL-10
  Guo et al., 2007 \[[@B31]\]         Acupuncture + traditional Chinese medicine enema                                                                          Traditional Chinese medicine enema                                                                Efficacy, intestinal microscopy
  Wang et al., 2009 \[[@B32]\]        Electroacupuncture + ginger moxibustion + traditional Chinese and western medicine enema                                  Traditional Chinese and western medicine enema                                                    Efficacy
  Long and Yang, 2010 \[[@B33]\]      Acupuncture + traditional Chinese medicine enema                                                                          Traditional Chinese medicine enema                                                                Efficacy, colonoscopy
  Chen, 2010 \[[@B34]\]               Acupuncture + ginger moxibustion + traditional Chinese medicine enema                                                     Traditional Chinese medicine enema                                                                Efficacy
  Sun and Wang, 2001 \[[@B35]\]       Acupuncture + ginger moxibustion                                                                                          Shuanghuanglian compound + norfloxacin + gentamicin                                               Efficacy
  Wang et al., 2006 \[[@B36]\]        Warm acupuncture                                                                                                          SASP                                                                                              Efficacy
  Shi et al., 2006 \[[@B37]\]         Electroacupuncture + moxibustion                                                                                          SASP                                                                                              Efficacy, serum levels of TNF-*α*, IL-8, IL-l, and IL-10
  Qun et al., 2012 \[[@B38]\]         Acupuncture + moxibustion + TDP                                                                                           SASP                                                                                              Efficacy, intestinal mucosa pathology, immunoglobulin
  Xu, 2006 \[[@B39]\]                 Ginger moxibustion + SASP                                                                                                 SASP                                                                                              Efficacy
  Zhang et al., 2011 \[[@B40]\]       Traditional acupuncture + Chinese medicine decoction                                                                      SASP                                                                                              Efficacy, symptom scores, serum levels of IL-8 and IL-10
  Joos et al., 2006 \[[@B41]\]        Traditional acupuncture + moxibustion                                                                                     Sham acupuncture                                                                                  CAI, QLO, general well-being, C-reactive protein, serum *α* ~1~-acid glycoprotein
  Yang and Yan, 1999 \[[@B42]\]       Acupuncture + moxibustion                                                                                                 SASP                                                                                              Efficacy, routine examination of faeces, electrogastrograms, sigmoidoscopy
  Joos et al., 2004 \[[@B43]\]        Traditional acupuncture + moxibustion                                                                                     Sham acupuncture                                                                                  CDAI, QLO, general condition, C-reactive protein, serum *α* ~1~-acid glycoprotein
  Ma, 1999 \[[@B44]\]                 Acupuncture + sparrow-pecking moxibustion                                                                                 SASP                                                                                              Efficacy
  Ma, 2005 \[[@B45]\]                 Acupuncture                                                                                                               SASP                                                                                              Efficacy

SASP: sulphasalazine; IBDQ: Inflammatory Bowel Disease Questionnaire; CAI: Colitis Activity Index; QOL: quality of life; CDAI: Crohn\'s Disease Activity Index; PAT: pipemidic acid tablet; sham acupuncture: superficial needling at nonacupoints.

[^1]: Academic Editor: Yong-Qing Yang
